6-trifluoromethoxy-2-methylthiobenzo[d]thiazole | 1203461-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 6-trifluoromethoxy-2-methylthiobenzo[d]thiazole
• 英文别名: 6-trifluoromethoxy-2-(methylthio)benzothiazole；2-(Methylthio)-6-(trifluoromethoxy)benzo[d]thiazole；2-methylsulfanyl-6-(trifluoromethoxy)-1,3-benzothiazole
• CAS: 1203461-92-0
• 化学式: C₉H₆F₃NOS₂
• 分子量: 265.28
• InChiKey: GWVIGQKRGLIXCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  75.7
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-trifluoromethoxy-2-methylthiobenzo[d]thiazole 在 苯甲醚 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 14.0h， 生成 3-benzyl-2-((Z)-((E)-3-ethyl-5-(3-methyl-6-(trifluoromethoxy)benzo[d]thiazol-2(3H)-ylidene)-4-oxothiazolidin-2-ylidene)methyl)thiazol-3-ium chloride
  参考文献：
  名称：

  探索苯并噻唑玫瑰花青作为蛋白质-蛋白质与热休克蛋白 70 (Hsp70) 相互作用的变构抑制剂。

  摘要：

  癌细胞依靠伴侣热休克蛋白 70 (Hsp70) 来生存和增殖。最近，苯并噻唑罗丹青素已被证明与 Hsp70 上的变构位点结合，中断其与核苷酸交换因子 (NEF) 的结合并促进乳腺癌细胞系中的细胞死亡。然而，概念验证分子，如 JG-98，具有相对适中的效力（EC 50 ≈ 0.7–0.4 μM），并且在动物中迅速代谢。在这里，我们通过~300 种类似物的基于结构和特性的设计探索了这个化学系列，表明最有效的 EC 50提高了 10 倍以上值（~0.05 至 0.03 μM）对抗两种乳腺癌细胞。生物标志物和全基因组 CRISPRi 筛选证实 Hsp70 家族的成员是细胞靶点。基于这些结果，发现 JG-231 可减少 MDA-MB-231 异种移植模型（4 mg/kg，腹腔注射）中的肿瘤负荷。总之，这些研究支持 Hsp70 可能是抗癌治疗的有希望的靶点的假设。

  DOI：

  10.1021/acs.jmedchem.8b00583
• 作为产物：
  描述：

  碘甲烷 、 6-(trifluoromethoxy)-1,3-benzothiazole-2-thiol 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 6-trifluoromethoxy-2-methylthiobenzo[d]thiazole
  参考文献：
  名称：

  Novel KCNQ2/Q3 Agonists as Potential Therapeutics for Epilepsy and Neuropathic Pain

  摘要：

  Current drugs for the treatment of seizure disorders, although effective in many patients, still suffer from a number of failures and are not effective in some forms of resistant epilepsies. Historically, many of these drugs have multiple mechanisms of action including calcium and sodium channel blockade as well as GABAergic activity and thus a number of associated side effects. Modulation of the M-current through opening of KCNQ channels has been proposed as a way to attenuate neuroexcitability and have a therapeutic benefit for the treatment Of seizure disorders. Therefore, as part Of our program to identify new treatments for epilepsy, we set out to identify agonists of KCNQ channels. High throughput screening of our corporate collection led to the identification of 1, adamantane-1-carboxylic acid (3-methyl-3H-benzothiazol-2-ylidine) hydrazide, a potent KCNQ2/Q3 agonist. Herein, we describe the syntheses and structure-activity relationships of analogues of I its well as their in vivo activity in animal models of epilepsy and neuropathic pain.

  DOI：

  10.1021/jm901497b

文献信息

• The cross-coupling reaction of organoalane reagents with 2-methylthiobenzo[<i>d</i>]thiazoles<i>via</i>C–S bond cleavage catalyzed by nickel
  作者：Xin Jiang、Hongliu Xiao、Xiaoying Jia、Jiaxia Pu、Lirong Han、Qinghan Li

  DOI：10.1039/d3nj02026f

  日期：——

  2-methylthiobenzo[d]thiazoles with aryl and alkenylaluminum reagents. Various 2-(hetero)aryl and 2-alkenyl substituted benzo[d]thiazoles derivatives can be obtained with 31–94% isolated yields using 4 mol% NiCl2(dppf)/4 mol% 2,2′-bipyridine as the catalyst under mild reaction conditions. The coupling reaction can be carried out smoothly whether the electron donor group or electron withdrawing group is on the aromatic

  通过镍催化 2-甲硫基苯并[ d ]噻唑与芳基和烯基铝试剂的交叉偶联，开发了一种高效且简单的合成 2-取代苯并[ d ]噻唑的路线。使用 4 mol% NiCl 2 (dppf)/4 mol% 2,2'-联吡啶作为催化剂，可以得到各种 2-(杂)芳基和 2-烯基取代的苯并[ d ]噻唑衍生物，分离产率为 31-94%在温和的反应条件下。无论给电子基团或吸电子基团在有机铝试剂的芳香环上还是2-甲硫基苯并[ d]上，偶联反应都能顺利进行。]噻唑衍生物。此外，广泛的底物范围和典型的克级高效维持使该方案成为合成 2-取代苯并[d ]噻唑衍生物的潜在实用方法。根据实验结果，提出了一种可能的催化循环。
• Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein–Protein Interactions with Heat Shock Protein 70 (Hsp70)
  作者：Hao Shao、Xiaokai Li、Michael A. Moses、Luke A. Gilbert、Chakrapani Kalyanaraman、Zapporah T. Young、Margarita Chernova、Sara N. Journey、Jonathan S. Weissman、Byron Hann、Matthew P. Jacobson、Len Neckers、Jason E. Gestwicki

  DOI：10.1021/acs.jmedchem.8b00583

  日期：2018.7.26

  Cancer cells rely on the chaperone heat shock protein 70 (Hsp70) for survival and proliferation. Recently, benzothiazole rhodacyanines have been shown to bind an allosteric site on Hsp70, interrupting its binding to nucleotide-exchange factors (NEFs) and promoting cell death in breast cancer cell lines. However, proof-of-concept molecules, such as JG-98, have relatively modest potency (EC50 ≈ 0.7–0

  癌细胞依靠伴侣热休克蛋白 70 (Hsp70) 来生存和增殖。最近，苯并噻唑罗丹青素已被证明与 Hsp70 上的变构位点结合，中断其与核苷酸交换因子 (NEF) 的结合并促进乳腺癌细胞系中的细胞死亡。然而，概念验证分子，如 JG-98，具有相对适中的效力（EC 50 ≈ 0.7–0.4 μM），并且在动物中迅速代谢。在这里，我们通过~300 种类似物的基于结构和特性的设计探索了这个化学系列，表明最有效的 EC 50提高了 10 倍以上值（~0.05 至 0.03 μM）对抗两种乳腺癌细胞。生物标志物和全基因组 CRISPRi 筛选证实 Hsp70 家族的成员是细胞靶点。基于这些结果，发现 JG-231 可减少 MDA-MB-231 异种移植模型（4 mg/kg，腹腔注射）中的肿瘤负荷。总之，这些研究支持 Hsp70 可能是抗癌治疗的有希望的靶点的假设。
• Novel KCNQ2/Q3 Agonists as Potential Therapeutics for Epilepsy and Neuropathic Pain
  作者：Paul C. Fritch、Grant McNaughton-Smith、George S. Amato、James F. Burns、C. Wesley Eargle、Rosemarie Roeloffs、William Harrison、Leslie Jones、Alan D. Wickenden

  DOI：10.1021/jm901497b

  日期：2010.1.28

  Current drugs for the treatment of seizure disorders, although effective in many patients, still suffer from a number of failures and are not effective in some forms of resistant epilepsies. Historically, many of these drugs have multiple mechanisms of action including calcium and sodium channel blockade as well as GABAergic activity and thus a number of associated side effects. Modulation of the M-current through opening of KCNQ channels has been proposed as a way to attenuate neuroexcitability and have a therapeutic benefit for the treatment Of seizure disorders. Therefore, as part Of our program to identify new treatments for epilepsy, we set out to identify agonists of KCNQ channels. High throughput screening of our corporate collection led to the identification of 1, adamantane-1-carboxylic acid (3-methyl-3H-benzothiazol-2-ylidine) hydrazide, a potent KCNQ2/Q3 agonist. Herein, we describe the syntheses and structure-activity relationships of analogues of I its well as their in vivo activity in animal models of epilepsy and neuropathic pain.